$ZNTL

$2.07 -$0.14 (6.33%) Close

$ZNTL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$ZNTL Management Team

Mr. James Bucher

Chief Legal Officer and Corporate Secretary

Age 59

Compensation -

Sex Male

Mr. Scott Myers

Independent Chairman of the Board

Age 59

Compensation $1.032M USD

Sex Male

Ms. Julie Eastland

President

Chief Executive Officer

Director

Age 61

Compensation $8.189M USD

Sex Female

Dr. Ingmar Bruns

Chief Medical Officer

Age 50

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Mr. James Bucher Chief Legal Officer and Corporate Secretary	59	-	Male
Mr. Scott Myers Independent Chairman of the Board	59	$1.032M USD	Male
Ms. Julie Eastland President Chief Executive Officer Director	61	$8.189M USD	Female
Dr. Ingmar Bruns Chief Medical Officer	50	-	Male

Board of Directors

From the proxy statement filed Apr 30, 2026

Directors

serving now

Independent

4 of 5

stated in the proxy; 1 not stated

Average tenure

3.5 years

from year joined

CEO also chairs the board

Scott Myers

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
David Johnson	61	2020 6 years	Independent	Compensation · Chair	Aura (Nasdaq: AURA)	$139,251
Jan Skvarka, Ph.D.	59	2022 4 years	Independent	Audit Nominating and Corporate Governance · Chair	Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE)	$151,405
Julie Eastland CEO	62	2024 2 years	Not independent	None stated	None stated	Paid as CEO
Enoch Kariuki, Pharm.D.	44	2021 5 years	Not stated	None stated	None stated	$151,405
Scott Myers Board chair	60	2024 2 years	Independent	Compensation Nominating and Corporate Governance	None stated	$184,136
Luke Walker, M.D.	54	2024 2 years	Independent	Audit Nominating and Corporate Governance	Context Therapeutics Inc. (Nasdaq: CNTX)	$145,266

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 30, 2026

Matrix Capital Master Fund, LP

one of our then stockholders owning more than 5% of our outstanding Common Stock

$1.33 per share

December 2025

Company repurchased 7,500,000 shares of its common stock from Matrix at $1.33 per share under a Stock Purchase Agreement

Open in proxy

Cam Gallagher

our former President, interim Chief Financial Officer and interim Treasurer and a former member of our Board

Zero dollars

For the years ended December 31, 2024, and December 31, 2025

License agreement under which Zeno Pharmaceuticals, Inc. was granted an exclusive worldwide license; Gallagher is a managing member of and holds an ownership interest in Recurium IP; zero milestone fees paid to Recurium IP

With Recurium IP Holdings, LLC Open in proxy

Comments

Company Executives

$ZNTL Management Team

Mr. James Bucher

Mr. Scott Myers

Ms. Julie Eastland

Dr. Ingmar Bruns

Board of Directors

Related-party transactions